Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis. - Wikidata - wikimedia - TriplyDB

Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis.

Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis.

http://www.wikidata.org/entity/Q34384728

about

Functions of TET Proteins in Hematopoietic Transformation Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis Rapid detection of DNMT3A R882 mutations in hematologic malignancies using a novel bead-based suspension assay with BNA(NC) probes DNMT3A in haematological malignancies.Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future.Enforced differentiation of Dnmt3a-null bone marrow leads to failure with c-Kit mutations driving leukemic transformation Familial occurrence of systemic mast cell activation disease.Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis Mutational Hotspot of TET2, IDH1, IDH2, SRSF2, SF3B1, KRAS, and NRAS from Human Systemic Mastocytosis Are Not Conserved in Canine Mast Cell Tumors Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex.Mastocytosis: a mutated KIT receptor induced myeloproliferative disorder Pak and Rac GTPases promote oncogenic KIT-induced neoplasms.ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases.Role of the ubiquitin proteasome system in hematologic malignancies.Mastocytosis: the puzzling clinical spectrum and challenging diagnostic aspects of an enigmatic disease.The transcriptional program, functional heterogeneity, and clinical targeting of mast cells.Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts.Reduced DNA methylation and hydroxymethylation in patients with systemic mastocytosis.Dnmt3a restrains mast cell inflammatory responses.Mastocytosis: a paradigmatic example of a rare disease with complex biology and pathology.Targeted Treatment Options in Mastocytosis.Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis.Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event.c-CBL regulates melanoma proliferation, migration, invasion and the FAK-SRC-GRB2 nexus.SF3B1 mutations are infrequently found in non-myelodysplastic bone marrow failure syndromes and mast cell diseases but, if present, are associated with the ring sideroblast phenotype Pilot assessment of vascular endothelial growth factor receptors and trafficking pathways in recurrent and metastatic canine subcutaneous mast cell tumours.Epigenetic and transcriptional control of mast cell responses.Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.Mutational profiling in the peripheral blood leukocytes of patients with systemic mast cell activation syndrome using next-generation sequencing.Midostaurin: a magic bullet that blocks mast cell expansion and activation.Infliction of proteotoxic stresses by impairment of the unfolded protein response or proteasomal inhibition as a therapeutic strategy for mast cell leukemia.Shared clonal cytogenetic abnormalities in aberrant mast cells and leukemic myeloid blasts detected by single nucleotide polymorphism microarray-based whole-genome scanning.The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis.Impact of centralized evaluation of bone marrow histology in systemic mastocytosis.Loss of epigenetic regulator TET2 and oncogenic KIT regulate myeloid cell transformation via PI3K pathway.

P2860

Q26778323-A37D43B1-CCB1-4747-87AB-E9418E6B7A37 Q27334940-77D5CEFB-AAA5-4C6C-BB50-DA89C36F95EF Q33734576-DF8E6E7F-B5D0-45C9-9644-E513EE26BBF6 Q34463554-61FDBC2F-ECEB-4D5C-9C77-EB24A89401C0 Q34552564-B05929E2-BFEC-48D5-B766-755D00BC0F25 Q35004935-E9790BC3-3427-40A4-BF57-0B55F8138460 Q35010297-38DF76F3-7CD7-414E-87D1-ED31DCA8CDD4 Q35235210-18B66044-E2E2-41FA-A8DE-B5DB9764D599 Q35839839-28765136-D704-40B6-9563-A4ECF12E0183 Q36018603-6D8BA5E0-90A7-4646-AA07-C5C590D6CD52 Q36210845-923D4E51-6AC8-4EDE-B42F-DD5C7150D44D Q37200848-3F150A85-E4B5-4EF5-92CD-125F494487B3 Q37499442-CF0E0C1D-1E9A-4467-AB2F-D31DF148AD6F Q38289055-9861131B-48FF-4CF0-9481-F1B60822A783 Q38582624-D37CFFA5-B910-4F96-AB26-E20FD39B75FC Q38642037-015C92CE-D3E7-4116-89BD-6B545C0F5015 Q38777126-C8FDDAD0-3C4C-4288-B600-BA0488960FA6 Q38908801-91D2C210-4B48-44A5-A7D9-8BE50561C39B Q38975300-946B5459-D3B7-475D-862A-2EFD85FB6051 Q39779573-D0505E49-896D-4F59-B0BE-F6617028C961 Q41061871-0FB63F1B-002A-409D-9E90-6F10C4DFB417 Q41225286-00542A78-AB83-4326-8E54-F44FD60469C4 Q41612115-3EA6CD82-D635-4142-B126-40B47030DA81 Q42059163-FB233DCB-FC53-4875-A7D0-B782229D1224 Q42583765-BB3CF76D-F57B-480F-9EFD-76861858BE76 Q42682714-01C4C92A-4EB2-40A4-AF63-E774C3EE06FB Q47119776-E2823809-14B8-4C8F-8741-B2C9ECD938EB Q47727992-8AD99C36-4D3B-4D13-9A89-E12DF455FE4E Q47896520-5D473A9F-175C-4E3C-8070-6CD522D8314E Q47930594-0D495FBE-D86D-49C5-9F7B-6740B5FF9EE0 Q48505281-82148C14-AE4A-4B6A-AFF4-19596B9713CF Q52885281-6CE9FBC4-7D8A-4710-A258-16FD4010DAC1 Q54234141-1A5F5BCE-75F6-4C71-95E1-CCE7511F3767 Q55029786-91DF8B66-BA96-49A8-96F0-D69931375A10 Q55266073-9958A738-4D04-416B-A0C5-942DD25CB5A9

P2860

Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis.

http://www.wikidata.org/entity/Q34384728

description

2012 nî lūn-bûn

@nan

2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Single nucleotide polymorphism ...... sent in systemic mastocytosis.

@ast

Single nucleotide polymorphism ...... sent in systemic mastocytosis.

@en

Single nucleotide polymorphism ...... sent in systemic mastocytosis.

@nl

type

label

Single nucleotide polymorphism ...... sent in systemic mastocytosis.

@ast

Single nucleotide polymorphism ...... sent in systemic mastocytosis.

@en

Single nucleotide polymorphism ...... sent in systemic mastocytosis.

@nl

prefLabel

Single nucleotide polymorphism ...... sent in systemic mastocytosis.

@ast

Single nucleotide polymorphism ...... sent in systemic mastocytosis.

@en

Single nucleotide polymorphism ...... sent in systemic mastocytosis.

@nl

P1433

Q34384728-3D7E3FEA-AC2B-4113-8C18-3440BD680D58

P1476

Q34384728-364A1031-2EDC-4BFF-9CEC-0A6D8BECADCE

P2093

Q34384728-0A346DF2-547A-4CC8-8472-7B64DE4C9994

Q34384728-0DD91616-F737-4CC2-96AF-6DD9D1F256E1

Q34384728-27416633-A5AE-4FA9-9B27-404EFA5AEE2B

Q34384728-38B0D891-3A5A-45EA-A440-AA7321F31943

Q34384728-4E6FBF04-AFC9-46C8-90F0-6A3C3849F690

Q34384728-54F25503-5FA6-4416-8BFB-74A571FBFED1

Q34384728-734EED85-D80C-4FDD-AD36-E7A604CBE95F

Q34384728-7E2C7A1E-89C4-4F54-98D1-88BCA653F8B7

Q34384728-83FE4112-14EE-4563-BEE2-D3EC8B4F576E

Q34384728-97DC7BE9-EEC5-4BDF-8048-5D00885AAB3B

P2860

Q34384728-0CA07648-C250-4723-9A13-23E52BCFABFD

Q34384728-12604349-7E9D-43B7-A419-6DB3896A628E

Q34384728-12810E17-999E-4714-9485-3B52B95AF153

Q34384728-2244DA98-92BC-48CD-AE3C-C3EE2A849139

Q34384728-22DB65F6-3BA8-485B-B3C2-DB648B5697CD

Q34384728-28622092-1EB0-495B-B5B4-E0709588D627

Q34384728-355F8813-9573-4ABF-8B5D-91D3CA9632C3

Q34384728-3E0F201E-FD8C-457F-B271-8819B9DA1134

Q34384728-49BB5799-0EEA-4496-95A7-D0FBE50C54D4

Q34384728-4E68C435-D54F-4198-B87D-D5CD6F342A70

P304

Q34384728-4878504F-CF7F-4A28-BAAB-B90F834DB515

P31

Q34384728-DADC97F0-19EB-4590-8AC8-7E1553492D69

P356

Q34384728-167C7E03-7524-4296-A3B6-2E8082B443E3

P407

Q34384728-49844A8E-5F63-4750-9E7D-A39797344E22

P433

Q34384728-9F763102-A67B-4B73-9BCA-753D74EB3656

P478

Q34384728-2512CF8E-605B-4E80-AB52-95936163C695

P50

Q34384728-FBC4C920-454D-4BFD-BF4E-EBB2E3ABCCE3

P577

Q34384728-8F39E36C-970B-4A44-A183-7BF109AB015A

P5875

Q34384728-AECF958F-48F1-4FCB-A141-F00058E5C6F8

P698

Q34384728-DF5398A5-5D12-494B-9CA0-5016BA15B7E1

P921

Q34384728-2D93433F-1ED9-4C33-BCA7-EE8DA656B339

P932

Q34384728-FDA36069-848F-4B6F-B931-E3B79644D6AB

P356

JOURNAL.PONE.0043090

P1433

P1476

Single nucleotide polymorphism ...... esent in systemic mastocytosis

@en

P2093

Alan E Lichtin

http://www.w3.org/2001/XMLSchema#string

Anjali S Advani

http://www.w3.org/2001/XMLSchema#string

Anna M Jankowska

http://www.w3.org/2001/XMLSchema#string

Christine L O'Keefe

http://www.w3.org/2001/XMLSchema#string

Edward Copelan

http://www.w3.org/2001/XMLSchema#string

Fred H Hsieh

http://www.w3.org/2001/XMLSchema#string

Hideki Makishima

http://www.w3.org/2001/XMLSchema#string

Hien K Duong

http://www.w3.org/2001/XMLSchema#string

Jaroslaw P Maciejewski

http://www.w3.org/2001/XMLSchema#string

Matt Kalaycio

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML

DNMT3A Mutations in Acute Myeloid Leukemia

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1

Recurrent DNMT3A mutations in patients with myelodysplastic syndromes

ASXL1 represses retinoic acid receptor-mediated transcription through associating with HP1 and LSD1

The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

Clinical effect of point mutations in myelodysplastic syndromes

Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder.

P304

e43090

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0043090

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-08-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230699946

http://www.w3.org/2001/XMLSchema#string

P698

22905207

http://www.w3.org/2001/XMLSchema#string

P921

single-nucleotide polymorphism

P932

3419680

http://www.w3.org/2001/XMLSchema#string